Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Exelixis proposes follow-on

EXEL proposed to sell 7 million shares in a follow-on underwritten

Read the full 114 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE